266 related articles for article (PubMed ID: 20053926)
1. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.
Kwon MJ; Kim SS; Choi YL; Jung HS; Balch C; Kim SH; Song YS; Marquez VE; Nephew KP; Shin YK
Carcinogenesis; 2010 Jun; 31(6):974-83. PubMed ID: 20053926
[TBL] [Abstract][Full Text] [Related]
2. Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma.
Kwon MJ; Kim SH; Jeong HM; Jung HS; Kim SS; Lee JE; Gye MC; Erkin OC; Koh SS; Choi YL; Park CK; Shin YK
Lab Invest; 2011 Nov; 91(11):1652-67. PubMed ID: 21844869
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the CLDN3 gene in ovarian cancer cells.
Honda H; Pazin MJ; D'Souza T; Ji H; Morin PJ
Cancer Biol Ther; 2007 Nov; 6(11):1733-42. PubMed ID: 17986852
[TBL] [Abstract][Full Text] [Related]
4. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells.
Honda H; Pazin MJ; Ji H; Wernyj RP; Morin PJ
J Biol Chem; 2006 Jul; 281(30):21433-21444. PubMed ID: 16714763
[TBL] [Abstract][Full Text] [Related]
5. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.
Rangel LB; Agarwal R; D'Souza T; Pizer ES; Alò PL; Lancaster WD; Gregoire L; Schwartz DR; Cho KR; Morin PJ
Clin Cancer Res; 2003 Jul; 9(7):2567-75. PubMed ID: 12855632
[TBL] [Abstract][Full Text] [Related]
6. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.
Shang X; Lin X; Alvarez E; Manorek G; Howell SB
Neoplasia; 2012 Oct; 14(10):974-85. PubMed ID: 23097631
[TBL] [Abstract][Full Text] [Related]
7. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
8. Potential roles of claudin-3 and claudin-4 in ovarian cancer management.
Uthayanan L; El-Bahrawy M
J Egypt Natl Canc Inst; 2022 Jun; 34(1):24. PubMed ID: 35665865
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4.
Lin X; Shang X; Manorek G; Howell SB
PLoS One; 2013; 8(6):e67496. PubMed ID: 23805314
[TBL] [Abstract][Full Text] [Related]
10. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
Yuan X; Lin X; Manorek G; Kanatani I; Cheung LH; Rosenblum MG; Howell SB
Mol Cancer Ther; 2009 Jul; 8(7):1906-15. PubMed ID: 19567823
[TBL] [Abstract][Full Text] [Related]
11. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
12. H4K20me3 co-localizes with activating histone modifications at transcriptionally dynamic regions in embryonic stem cells.
Xu J; Kidder BL
BMC Genomics; 2018 Jul; 19(1):514. PubMed ID: 29969988
[TBL] [Abstract][Full Text] [Related]
13. Histone modifications silence the GATA transcription factor genes in ovarian cancer.
Caslini C; Capo-chichi CD; Roland IH; Nicolas E; Yeung AT; Xu XX
Oncogene; 2006 Aug; 25(39):5446-61. PubMed ID: 16607277
[TBL] [Abstract][Full Text] [Related]
14. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis.
Huang YH; Bao Y; Peng W; Goldberg M; Love K; Bumcrot DA; Cole G; Langer R; Anderson DG; Sawicki JA
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3426-30. PubMed ID: 19208807
[TBL] [Abstract][Full Text] [Related]
15. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
16. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.
Meng CF; Su B; Li W
Mol Med Rep; 2011; 4(6):1273-8. PubMed ID: 21850374
[TBL] [Abstract][Full Text] [Related]
17. Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.
Curry E; Zeller C; Masrour N; Patten DK; Gallon J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Bowtell DD; Brown R
Cancer Res; 2018 Mar; 78(6):1383-1391. PubMed ID: 29339543
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cancer-associated genes in ovarian cancer.
Kwon MJ; Shin YK
Int J Mol Sci; 2011 Jan; 12(2):983-1008. PubMed ID: 21541038
[TBL] [Abstract][Full Text] [Related]
19. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA; Hinchcliffe EH; Robinson JP
Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
[TBL] [Abstract][Full Text] [Related]
20. Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.
Yeh KT; Chen TH; Yang HW; Chou JL; Chen LY; Yeh CM; Chen YH; Lin RI; Su HY; Chen GC; Deatherage DE; Huang YW; Yan PS; Lin HJ; Nephew KP; Huang TH; Lai HC; Chan MW
Epigenetics; 2011 Jun; 6(6):727-39. PubMed ID: 21540640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
